Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Brand name: Spikevax Bivalent Original/Omicron BA.4-5 TM
Active ingredients: elasomeran + davesomeran
What it is used for
SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 (elasomeran/davesomeran) COVID-19 Vaccine is indicated for:,As a booster dose for active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 12 years of age and older who have previously received at least a primary vaccination course against COVID-19.,The use of this vaccine should be in accordance with official recommendations.
How to take it
The way to take this medicine is: Intramuscular. This medicine is given through a needle inserted into the muscle beneath the skin.
- Store between minus 50 - minus 15 degrees Celsius
- Protect from Light
- Store in Original Container
- Shelf lifetime is 9 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
White to off-white frozen suspension
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Need more information?
These trusted information partners have more on this topic.
Top results
COVID-19 vaccines: Frequently asked questions (FAQs) | NCIRS
COVID-19 vaccines: Frequently asked questions (FAQs) COVID-19 Australian Immunisation Handbook COVID-19 vaccines Immunisation coverage data and reports Education and training History of immunisation Immunisation schedules National and international resources NCIRS fact sheets, FAQs and other resources COVID-19 DTPa-HB-IPV-Hib vaccine (Vaxelis® and Infanrix hexa®) Haemophilus influenzae type b (Hib) Hepatitis B Human papillomavirus Influenza Japanese encephalitis Measles Measles vaccination catch-up guide Meningococcal Mpox (formerly known as monkeypox) Mumps Pertussis Pneumococcal Poliomyelitis Respiratory syncytial virus (RSV) Rotavirus Rubella Varicella-zoster (chickenpox) Zoster (shingles) Injection site reactions Vaccine components Vaccines for Australian adults Vaccinations during pregnancy NCIRS webinar series Patient communication resources Specialist immunisation services SKAI - supporting health professionals NCIRS newsletters Vaccine safety COVID-19 Australian Immunisation Handbook COVID-19 vaccines Immunisation coverage data and reports Education and training History of immunisation Immunisation schedules National and international resources NCIRS fact sheets, FAQs and other resources COVID-19 DTPa-HB-IPV-Hib vaccine (Vaxelis® and Infanrix hexa®) Haemophilus influenzae type b (Hib) Hepatitis B Human papillomavirus Influenza Japanese encephalitis Measles Measles vaccination catch-up guide Meningococcal Mpox (formerly known as monkeypox) Mumps Pertussis Pneumococcal Poliomyelitis Respiratory syncytial virus (RSV) Rotavirus Rubella Varicella-zoster (chickenpox) Zoster (shingles) Injection site reactions Vaccine components Vaccines for Australian adults Vaccinations during pregnancy NCIRS webinar series Patient communication resources Specialist immunisation services SKAI - supporting health professionals NCIRS newsletters Vaccine safety Key points COVID-19 is a disease caused by the SARS-CoV-2 virus
Read more on National Centre for Immunisation Research and Surveillance (NCIRS) website
Top results
COVID-19 vaccines in 2023 - Australian Prescriber
As SARS‑CoV‑2 continues to evolve, vaccines are being updated, and policymakers are reviewing the optimal timing of future booster doses to maintain adequate protection against severe illness, particularly for older adults.
Read more on Australian Prescriber website